No Benefit of Saxagliptin on Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Potential Explanations

被引：1
|
作者：
Jialal, Ishwarlal [1 ]
Dhindsa, Sandeep [2 ]
机构：
[1] Univ Calif Davis, Med Ctr, Lab Atherosclerosis & Metab Res, Sacramento, CA 95817 USA
[2] Texas Tech Univ, Hlth Sci Ctr, Div Endocrinol & Metab, Odessa, TX USA
来源：
METABOLIC SYNDROME AND RELATED DISORDERS | 2014年 / 12卷 / 03期
关键词：
DIPEPTIDYL PEPTIDASE-4 INHIBITORS; THERAPY;
D O I：
10.1089/met.2014.1500
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：157 / 158
页数：2
相关论文
共 50 条
  • [41] Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
    Konig, Manige
    Riddle, Matthew C.
    Colhoun, Helen M.
    Branch, Kelley R.
    Atisso, Charles M.
    Lakshmanan, Mark C.
    Mody, Reema
    Raha, Sohini
    Gerstein, Hertzel C.
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [42] Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
    Manige Konig
    Matthew C. Riddle
    Helen M. Colhoun
    Kelley R. Branch
    Charles M. Atisso
    Mark C. Lakshmanan
    Reema Mody
    Sohini Raha
    Hertzel C. Gerstein
    Cardiovascular Diabetology, 20
  • [43] Influence of variability in risk factors on cardiovascular disease outcomes in type 2 diabetes mellitus
    Uzokov, Jamol
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023,
  • [44] Outcomes of Patients With Type 2 Diabetes at High Risk of Cardiovascular Events Treated With Saxagliptin: Outcomes by Baseline HgbA1c
    Cavender, Matthew A.
    Scirica, Benjamin M.
    Raz, Itamar
    Steg, P. G.
    Hirshberg, Boaz
    Davidson, Jaime
    Im, KyungAh
    Hoffman, Elaine
    Braunwald, Eugene
    Bhatt, Deepak L.
    CIRCULATION, 2013, 128 (22)
  • [45] Predictors of long-term cardiovascular outcomes in patients with type 2 diabetes mellitus
    Bianco, H.
    Helfenstein, T.
    Izar, M. C.
    Fonseca, H. A.
    Fischer, S. C.
    Ferreira, C. E.
    Xavier, H. T.
    Povoa, R. M.
    Fonseca, F. A.
    EUROPEAN HEART JOURNAL, 2012, 33 : 893 - 893
  • [46] Intensive glycaemic control in type 2 diabetes mellitus: Does it improve cardiovascular outcomes?
    Reddy, Sagili Vijaya Bhaskar
    Bhatia, Eesh
    NATIONAL MEDICAL JOURNAL OF INDIA, 2011, 24 (01): : 21 - 27
  • [47] Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
    Abd A. Tahrani
    Milan K. Piya
    Anthony H. Barnett
    Advances in Therapy, 2009, 26 : 249 - 262
  • [48] Resource Use of Type 2 Diabetes Mellitus Patients Following Initiation With Saxagliptin or Sitagliptin
    Ivanova, Jasmina
    Kaltenboeck, Anna
    Bell, Kelly
    Thomas, Nina
    Schwiep, Frances
    Yushkina, Yana
    Birnbaum, Howard
    DIABETES, 2013, 62 : A330 - A330
  • [49] COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN RUSSIA
    Arinina, E. E.
    Rashyd, M.
    VALUE IN HEALTH, 2012, 15 (04) : A172 - A172
  • [50] Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
    Tahrani, Abd A.
    Piya, Milan K.
    Barnett, Anthony H.
    ADVANCES IN THERAPY, 2009, 26 (03) : 249 - 262
12345